Virbac SA (EPA:VIRP)
France
· Delayed Price · Currency is EUR | Market Cap | 3.12B |
| Revenue (ttm) | 1.46B |
| Net Income (ttm) | 150.89M |
| Shares Out | 8.38M |
| EPS (ttm) | n/a |
| PE Ratio | 20.71 |
| Forward PE | 17.70 |
| Dividend | 1.45 (0.39%) |
| Ex-Dividend Date | Jun 24, 2025 |
| Volume | 2,671 |
| Average Volume | 3,878 |
| Open | 372.00 |
| Previous Close | 373.00 |
| Day's Range | 366.00 - 372.00 |
| 52-Week Range | 296.00 - 389.50 |
| Beta | 0.81 |
| RSI | 51.20 |
| Earnings Date | Sep 17, 2026 |
About Virbac
Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, and the Pacific. The company offers a range of vaccines, antibiotics, parasiticides, and anti-inflammatory drugs, as well as dermatology, dental, specialty, diagnosis, nutrition, petfood, and pharmaceutical products. It serves veterinarians, farmers, and pet owners. The company was founded in 1968 and is headquartered in Carros, France. [Read more]
Financial Performance
In 2025, Virbac's revenue was 1.46 billion, an increase of 4.82% compared to the previous year's 1.40 billion. Earnings were 150.89 million, an increase of 3.85%.
Financial StatementsNews
Virbac : Public release of Virbac Annual Report at 31 December 2025.
Public release of Virbac Annual Report at 31 December 2025. The Group released and filed its 2025 Annual Report with the French “Autorité des marchés financiers”, at the ESEF format.
Virbac: strong Q1 2026 growth of +7.7% at CERS, driven by double-digit growth of our priority Supercharge4 platforms
First-quarter 2026 revenue reached €384m : +7.7% at constant exchange rate and scope (CERS) vs Q1 2025 +2.2% at actual rates impacted by significant currency headwinds Balanced growth in both segments...
Virbac : Declaration of the number of shares and voting rights 03/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the Fr...
Virbac Earnings Call Transcript: H2 2025
Delivered 7.9% organic revenue growth and stable margins in 2025, with strong performance across all regions and segments. Record R&D and CapEx investments, a key acquisition, and a refreshed strategy position the company for continued outperformance, with 2026 guidance targeting higher margins and robust cash flow.
Virbac: Public Release of the Year-End Consolidated Accounts at 31 December 2025
Public release of Virbac Consolidated Accounts at 31 December 2025. The Group released its 2025 Consolidated Accounts.
Virbac: 2025 annual results
A robust adjusted EBIT margin² of 16.3% at CERS, driven by solid organic revenue growth of 7.9% Solid 2025 dynamic with annual revenue up +7.9% at CERS; with strong momentum in key categories and coun...
Virbac : Declaration of the number of shares and voting rights 02/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the Fr...
Virbac : Declaration of the number of shares and voting rights 01/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the Fr...
Virbac : Declaration of the number of shares and voting rights 11/2025
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital(Article 223-16 of the General regulations of the Fre...
VIRBAC Announces Third Quarter 2025 Sales
Sustained revenue growth at the end of September of +7.8% at constant exchange rates and scope Upgrade of the full-year revenue guidance Revenue growth now expected to be between 5.5% and 7.5% at cons...
Virbac Earnings Call Transcript: H1 2025
Solid H1 2025 results with 5.6% organic growth, strong performance across most regions, and robust new product launches. EBIT margin declined due to temporary effects, but full-year guidance and 2030 margin targets are reaffirmed. CapEx and M&A activity remain high priorities.
Virbac: 2025 Half-year results
Solid revenue growth in the first half of 2025 of +5.6% at constant exchange rates and scope.
Virbac : Public release of the Half-Year Financial Report at 30 June 2025.
The Group released and filed its 2025 half-year financial report with the French “Autorité des marchés financiers”. The document is also available on the corporate website, at corporate.virbac.com, un...
Virbac : Half-yearly financial report 2025
Please find attached 2025 Half-yearly financial report of Virbac Attachment Half-Yearly Financial Report_2025
Virbac:: Paul Martingell's compensation terms
The board of directors, acting upon the recommendation of the appointments and compensation committee, has approved the compensation terms for Paul Martingell for the duration of his mandate, as detai...
Virbac: in the first half of 2025, revenue recorded solid growth of +5.6% at constant exchange rates and scope of consolidation
Quarterly consolidated revenue Our second-quarter revenue reached €363.1 million, marking a +6.4% increase at constant exchange rates and scope compared to the same period in 2024. This strong quarter...
VIRBAC: Paul Martingell is appointed chief executive officer of Virbac, effective September 1, 2025
Virbac announces the appointment of Paul Martingell as the chief executive officer of the Virbac group, effective September 1, 2025.
Virbac : Public release of Virbac Annual Report at 31 December 2024
The Group released and filed its 2024 Annual Report with the French “Autorité des marchés financiers”, at the ESEF Format. Additionally, the report is attached at the PDF format.
Virbac: In the first quarter of 2025, revenue recorded solid growth of +4.9% at constant exchange rates and scope
In the first quarter of 2025, revenue recorded solid growth of +4.9% at constant exchange rates and scope KEY FIGURES Revenue 1st quarter 2025 €375.2 M Growth at constant exchange rates and scope 1 +4...
Pet Dental Health Market Forecast Report 2025-2030, with Petdentist, Virbac, Animal Dental Clinic, iM3, The Happy Jack Co., Pet Kare Clinic, Felican Pet Hospital, Ruddington Vets, Pets'n'Vets and more
Dublin, April 14, 2025 (GLOBE NEWSWIRE) -- The "Pet Dental Health Market - Forecasts from 2025 to 2030" report has been added to ResearchAndMarkets.com's offering. The Pet Dental Health Market, valued...
Virbac Earnings Call Transcript: H2 2024
Revenue grew 13.6% in 2024, driven by balanced organic and acquisition growth, with record EBIT margin and strong cash flow. Outlook for 2025 is 4%-6% revenue growth, stable profitability, and continued high CapEx for transformation.
Virbac: Public Release of the Year-End Consolidated Accounts at 31 December 2024
Public release of Virbac Consolidated Accounts at 31 December 2024. The Group released its 2024 Consolidated Accounts.
Virbac: 2024 Annual results
1 variance at constant exchange rates and scope corresponds to the organic growth of sales, excluding exchange rate variations, by calculating the indicator for the financial year in question and the ...
Virbac: Strong annual revenue growth of +13.6% supported by dynamic organic growth (+7.5%) and the strategic contribution of our acquisitions (+6.1%)
Strong annual revenue growth of +13.6% supported by dynamic organic growth (+7.5%) and the strategic contribution of our acquisitions (+6.1%)
Virbac : Declaration of the number of shares and voti
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital(Article 223-16 of the General regulations of the Fre...